Serglycin expression in CD2+and CD14+cells from patients with various rheumatic diseases

The objective of the study was to look at the in vivo expression of serglyc in in cells taken from patients with an inflammatory disease. The mRNA expr ession of the small proteoglycan serglycin was investigated in macrophages; monocytes and T-cells derived from the synovial fluid and blood or six pati ents with various rheumatic diseases and from the blood of two control subj ects. Our results demonstrate higher levels of expression in CD14+ cells ta ken from patients with chronic inflammatory diseases than in control subjec ts. This suggests that serglycin may play a role during the inflammatory pr ocess.